Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Gottlieb vote
The Pharmalot View

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

By Ed Silverman

Nasal spray black and white
Health

FDA approves esketamine, the first major depression treatment to reach U.S. market in decades

By Megan Thielking

Chemotherapy infusion
Pharmalot

Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage

By Ed Silverman

Pharmalot

Pharmalittle: Purdue considers filing bankruptcy as lawsuits mount; pharma fights over poop

By Ed Silverman

Pharma

Archived: An online chat discussing the future of real-world evidence

By Matthew Herper

Botox Chronic Pain
Pharmalot

ITC agrees to investigate Allergan claims that Botox rivals stole secrets

By Ed Silverman

Bribery
Pharmalot

What financial ties? Most Americans were unaware of database showing pharma payments to docs

By Ed Silverman

Pharmalot

Pharmalittle: Lilly to sell version of insulin at half price; senators push drug price gouging bill

By Ed Silverman

Eli Lilly insulin
Pharmalot

Lilly will sell a version of its popular insulin at half the price, but will this appease critics?

By Ed Silverman

Maura Healey - Purdue suit
Health

Opioid maker Purdue Pharma seeks to have Massachusetts lawsuit thrown out

By Andrew Joseph

Pharmalot

Novartis agrees to pay $23m following charges it used charities to pay kickbacks to Medicare patients

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Dengue Vaccine Protesters
Pharmalot

Sanofi faces indictment in the Philippines over deaths related to its dengue vaccine

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer is probed for problems at EpiPen plant; despite disappointments, Mylan CEO gets a raise

By Ed Silverman

DEA Prescription Drug
Pharmalot

As more lawmakers look to import cheaper meds, FDA warns a Canadian broker

By Ed Silverman

Bernie Sanders
Pharmalot

Sanders asks FDA to allow sales of older versions of $375,000 rare-disease drug

By Ed Silverman

Bristol-Myers Squibb
Pharmalot

Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

By Ed Silverman

Pharmalot

Pharmalittle: Big Bristol-Myers shareholder opposes Celgene deal; Novartis can’t escape Cohen debacle

By Ed Silverman

D.C. Insight IMAGE
Politics

Webinar: Is the new Congress ready to lower drug costs?

By Lev Facher and Nicholas Florko

Seven up
Pharmalot

Did some pharma execs offer misleading testimony to a Senate committee?

By Ed Silverman

Pharmalot

Pharmalittle: FDA plans new steps to combat opioid abuse; pharma execs dodged a bullet at hearing

By Ed Silverman

BiTE Bridge
Pharma

They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

By Sharon Begley

Richard A. Gonzalez and others testifying
Pharma

Who shined and who sank: How seven executives fared in defending pharma

By Matthew Herper and Nicholas Florko

NJ: Corporations In New Jersey
Pharmalot

Former Novartis exec wins $1.5 million after claiming she was fired for complaining about a study

By Ed Silverman

FDA new drugs - historical
Pharmalot

A small drug maker settles charges for paying others to submit its FDA applications

By Ed Silverman

Pharma CEO photo illustration
Politics

A letter from Executive Editor Rick Berke: All eyes on today’s drug pricing hearing

By Rick Berke

Pharmalot

Pharmalittle: Watch the Senate hearing on drug prices here; Amgen wins a patent ruling on its cholesterol drug

By Ed Silverman

Britain Economy
Pharmalot

U.K. agrees to improve clinical trial transparency, but lack of funding is ‘disappointing’

By Ed Silverman

Botox Chronic Pain
Pharmalot

Is Allergan too ‘sanguine’ over new competition for its best-selling Botox treatment?

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy